证券日报网讯 9月1日晚间，九强生物发布公告称，公司于近期收到中华人民共和国国家知识产权局颁 发的4项专利证书。 （文章来源：证券日报） ...

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. has recently received four patent certificates from the National Intellectual Property Administration of the People's Republic of China, which will enhance the company's intellectual property advantages and promote technological innovation [1][2]. Patent Information - The patents include a novel variant of glucose-6-phosphate dehydrogenase with mutations D306C, D375C, and G426C, which results in a detection kit that is highly specific, sensitive, easy to operate, has a short detection time, and provides accurate quantification, suitable for high-throughput testing [1][2]. Impact on the Company - The acquisition of these patents is not expected to have a significant immediate impact on the company's production and operations, but it will strengthen the company's core competitiveness and establish a mechanism for continuous innovation [2].

关于公司获得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 4 项专利证书，具体情况如下： | 序号 | 专利号 | 专利名称 | 专利权人 | 专利类型 | 申请日期 | 授权日期 | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | ZL202310 217235.5 | 偶联物的制 备方法 | 九强生物 | 发明 | 2019.12.26 | 2025.08.26第 | 8198527 | 号 | | 2 | ZL202310 553479.0 | 偶联物在制 备检测试剂 中的用途 | 九强生物 | 发明 | 2020.01.07 | 2025.08.26第 | 8193337 | 号 | | 3 | ZL202310 725902.0 | 偶联物在制 备检测试剂 中的用途 | 九强生物 | 发明 | 2020.01.08 | 2025.0 ...

Core Viewpoint - The company has announced an adjustment to the conversion price of its convertible bonds due to changes in its share capital structure following a cash dividend distribution [1][2][4]. Summary by Sections Conversion Price Adjustment Basis - The adjustment of the conversion price is based on the company's regulations regarding changes in share capital, including stock dividends, capital increases, and cash dividends [1][2]. Reason for Adjustment - The conversion price was adjusted because the company repurchased 3,544,084 shares that did not participate in the cash dividend distribution. The total cash dividend distributed was 174,829,363.20 yuan, calculated based on the number of shares participating in the distribution and the dividend per share of 0.30 yuan [2][3]. Result of Adjustment - The conversion price of the "Jiukang Convertible Bonds" will be adjusted from 16.98 yuan per share to 16.68 yuan per share, effective from September 5, 2025. This adjustment reflects the reduction in the cash dividend per share due to the repurchased shares [4].

Core Points - The company has announced its 2025 semi-annual profit distribution plan, which was approved by the shareholders' meeting and the board of directors [2][3] - The distribution plan involves a cash dividend of RMB 3.00 per 10 shares (including tax), with no capital reserve conversion into additional shares or bonus shares [2][3] - The total cash dividend amount is RMB 174,829,363.20 (including tax) [3] - The record date for the distribution is set for September 4, 2025, and the ex-dividend date is September 5, 2025 [5] - The distribution will not include 3,544,084 shares held in the company's repurchase account [6] - The conversion price for the company's convertible bonds will be adjusted from RMB 16.98 to RMB 16.68 per share effective from September 5, 2025 [6]

特别提示： 1、北京九强生物技术股份有限公司(以下简称"公司")通过集中竞价 交易方式回购的回购专用账户内的 3,544,084 股股份依法不参与本次权益 分 派 。 公 司 2025 年 半 年 度 权 益 分 派 方 案 为 ： 以 公 司 现 有 总 股 本 586,308,628 股减去公司回购专用证券账户不参与分配 3,544,084 股后的 582,764,544 股为基数，向全体股东每 10 股派发现金 3.00 元人民币（含 税），按照"分配比例不变"的原则，实际现金分红总额为人民币 174,829,363.20 元（含税）。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购 股份）折算每 10 股现金分红（含税）=实际现金分红总额/总股本× 10=174,829,363.20 元/586,308,628 股×10=2.981865 元（保留六位小数， 最后一位直接截取，不四舍五入）。本次权益分派实施后除权除息参考价= 除权除息日前一日收盘价-按总股本折算每股现金红利=除权除息日前一日 收盘价-0.2981865 元。 公司 2025 年半年度权益分派方案已获 2025 年 4 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-067 转债代码：123150 转债简称：九强转债 北京九强生物技术股份有限公司 关于九强转债转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 一、转股价格调整依据 根据《北京九强生物技术股份有限公司（以下简称"公司"）创业板向不特定对 象发行可转换公司债券募集说明书》以下简称（"《募集说明书》"）相关条款的规 定，在本次可转债发行之后，当公司因派送股票股利、转增股本、增发新股（不包括 因本次可转债转股而增加的股本）、配股、派送现金股利等情况使公司股份发生变化 时，将按下述公式进行转股价格的调整（保留小数点后两位，最后一位四舍五入）： 派送股票股利或转增股本：P1=P0/(1+n)； 增发新股或配股：P1=(P0+A×k)/(1+k)； 上述两项同时进行：P1=(P0+A×k)/(1+n+k)； 派送现金股利：P1=P0-D； 上述三项同时进行：P1=(P0-D+A×k)/(1+n+k) 调整前转股价格：16.98 元/股 调整后转股价格：16.68 元/股 转股价格 ...

据证券之星公开数据整理，近期九强生物(300406)发布2025年中报。截至本报告期末，公司营业总收入 6.68亿元，同比下降18.67%，归母净利润1.75亿元，同比下降30.01%。按单季度数据看，第二季度营业 总收入3.49亿元，同比下降18.54%，第二季度归母净利润9197.63万元，同比下降29.1%。本报告期九强 生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达197.93%。 财务报表中对有大幅变动的财务项目的原因说明如下：货币资金变动幅度为-15.76%,原因:分红和购买大 额存单等。所得税费用变动幅度为-59.46%,原因:利润下降。投资活动产生的现金流量净额变动幅度 为-179.81%,原因:本期购买大额存单。筹资活动产生的现金流量净额变动幅度为-108.43%,原因:本期股利 分配高于去年同期。现金及现金等价物净增加额变动幅度为-169.71%,原因:本期购买大额存单、股利分 配。 证券之星价投圈财报分析工具显示：业务评价：公司去年的ROIC为11.19%，资本回报率一般。然而去 年的净利率为32.02%，算上全部成本后，公司产品或服务的附加值极高。从历史年报数据统计来看 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-065 转债代码：123150 转债简称：九强转债 北京九强生物技术股份有限公司 关于实施权益分派期间九强转债暂停转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、债券代码：123150 债券简称：九强转债 2、转股期限：2023 年 1 月 6 日至 2028 年 6 月 29 日 增发新股或配股：P1=（P0+A×k）/（1+k）； 上述两项同时进行：P1=（P0+A×k）/（1+n+k）； 3、计划暂停转股时间：2025 年 8 月 28 日至 2025 年半年度权益分派股权登记日止 4、计划恢复转股时间：2025 年半年度权益分派股权登记日后的第一个交易日 北京九强生物技术股份有限公司（以下简称"公司"）将于近日实施公司 2025 年 半年度权益分派，根据《北京九强生物技术股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》中"转股价格的调整方式及计算公式"条款的规定（详见附 件）及有关业务办理指南的规定，自 2025 年 8 月 28 日起至 2 ...